To further explore the in vivo antitumor effects of thioparib in blood cancers, we used xenografts of the HR‐proficient MM.1 S cell line, the POLQ mutant MV‐4‐11 cell line, and the BRCA1/2‐deficient JeKo‐1 cell line (Xiao et al, 2008), all of which have different genetic backgrounds and high sensitivity to thioparib. This evidence concerns the gene BRCA1 and hematopoietic and lymphoid system neoplasm.